Visualize HL7 Example and Test Instances (vi7eti), pronounced /viːˈsɛtiː/
Disclaimer: FOR TEST AND EXAMPLE PURPOSES ONLY! These web pages are not intended to be used as a source of information on medicines. The web pages are not kept up to date and are for demonstration purposes only. For up-to-date information on a medicine, please consult www.ema.europa.eu/medicines or the package leaflet of your medicine.
BACK TO LIST

Laboratory Report

Patient
Name: Köster, , Louise,
DOB: 01-JUL-1957 (Age: 68)
Gender: female
Address:
Regina-Butte-Ring 737
88348 Saulgau (Germany)
ID: 1053-167357-1 (ECI)
Report
Date: 12-NOV-2019
Laboratory
dr Ample, Ex
Laboratoire Central Européenne
Boulevard du Jardin Botanique 32
1000 Brussels (Belgium)
Requested by
Klinik am schönen Moos
Am Schönen Moos 7
88348 Bad Saulgau (Germany)
Specimen
Collected: 12-NOV-2019

Chemistry

Test 12-NOV-2019 Reference Range Unit
Hemoglobin A1c/Hemoglobin.total in Blood 5.9 4.5 - 6.4 %
Glucose [Mass/volume] in Blood 70.5 70 - 140 mg/dL
Urea nitrogen [Mass/volume] in Blood 7.9 7 - 43 mg/dL
Creatinine [Mass/volume] in Blood 0.7 0.7 - 1.1 mg/dL
Calcium [Mass/volume] in Blood 9.8 8.5 - 10.4 mg/dL
Sodium [Moles/volume] in Blood 136.5 135 - 145 mmol/L
Potassium [Moles/volume] in Blood 4.5 3.5 - 5.1 mmol/L
Chloride [Moles/volume] in Blood 105.4 98 - 107 mmol/L
Carbon dioxide, total [Moles/volume] in Blood 22.4 22 - 32 mmol/L
Cholesterol [Mass/volume] in Serum or Plasma 191.5 125 - 200 mg/dL
Triglyceride [Mass/volume] in Serum or Plasma 103.5 35 - 150 mg/dL
Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay 117.2 0 - 130 mg/dL
Cholesterol in HDL [Mass/volume] in Serum or Plasma 53.5 50 - 100 mg/dL

Annotation

Conclusion and Recommendations based on this report and previous findings known to us
All measured parameters are within normal limits. Glycemic control (HbA1c, glucose), renal function (urea, creatinine), electrolytes, lipid profile, and calcium are all unremarkable. No laboratory evidence of acute or chronic metabolic, renal, or lipid abnormalities at this time. Recommend continued routine monitoring.